PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances and a third that has been filed for FDA approval.
PureTech established the underlying programs and platforms that resulted in 28 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Internal Programs

Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
100% Equity
Phase 2b
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

Founded Entities1

Neuropsychiatric conditions
61.5% Equity
Phase 2
Advancing transformative medicines for people living with psychiatric and neurological conditions
Milestone Payments/ Royalties & up to $400M in milestone payments from agreement w/Royalty Pharma2
Phase 3
Pioneering a new category of oral therapies based on defined bacterial consortia
36.1% Equity
Phase 3 Ready
Hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally advanced/metastatic solid tumors, including head and neck cancers
100% Equity
Phase 1/2
Engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers
3.9% Equity
Phase 1/2a
Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)
73.8% Equity
Preclinical
Pioneering the development of cognitive treatments through game-changing technologies
14.6% Equity
Commercial
A voice-based artificial intelligence platform to detect changes in health
35.2% Equity
Commercial Release

Note: PureTech retains control of Entrega, Inc. and Seaport Therapeutics, and they are consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc.
1 Relevant ownership interests for Vedanta and Sonde were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2023, and Seaport as of April 8, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Seaport Therapeutics, Inc. and Gallop Oncology, Inc. Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of May 7, 2024 and March 15, 2024, respectively.  
2 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

PureTech Level Cash, Cash Equivalents & Short-Term Investments

$573.3M
PureTech Level Cash, Cash Equivalents and Short-Term Investments
as of March 31, 20243

3 PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure.

Developing breakthrough medicines at PureTech